London · Delayed Price · Currency is GBP · Price in GBX AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of GBP 214.94 billion. The enterprise value is 234.93 billion.
| Market Cap | 214.94B |
| Enterprise Value | 234.93B |
Important Dates
The next confirmed earnings date is Monday, July 27, 2026.
| Earnings Date | Jul 27, 2026 |
| Ex-Dividend Date | Feb 19, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 64.85% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 27.56 and the forward PE ratio is 17.44. AstraZeneca's PEG ratio is 1.49.
| PE Ratio | 27.56 |
| Forward PE | 17.44 |
| PS Ratio | 4.70 |
| PB Ratio | 5.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.13 |
| P/OCF Ratio | 19.96 |
| PEG Ratio | 1.49 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.19, with an EV/FCF ratio of 27.47.
| EV / Earnings | 29.86 |
| EV / Sales | 5.13 |
| EV / EBITDA | 15.19 |
| EV / EBIT | 20.76 |
| EV / FCF | 27.47 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.91 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.67 |
| Debt / FCF | 3.01 |
| Interest Coverage | 10.61 |
Financial Efficiency
Return on equity (ROE) is 23.48% and return on invested capital (ROIC) is 16.44%.
| Return on Equity (ROE) | 23.48% |
| Return on Assets (ROA) | 8.49% |
| Return on Invested Capital (ROIC) | 16.44% |
| Return on Capital Employed (ROCE) | 18.36% |
| Weighted Average Cost of Capital (WACC) | 5.20% |
| Revenue Per Employee | 476,283 |
| Profits Per Employee | 81,869 |
| Employee Count | 96,100 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, AstraZeneca has paid 1.91 billion in taxes.
| Income Tax | 1.91B |
| Effective Tax Rate | 19.52% |
Stock Price Statistics
The stock price has increased by +12,772.00% in the last 52 weeks. The beta is 0.21, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +12,772.00% |
| 50-Day Moving Average | 141.35 |
| 200-Day Moving Average | 135.38 |
| Relative Strength Index (RSI) | 51.39 |
| Average Volume (20 Days) | 2,032,698 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of GBP 45.77 billion and earned 7.87 billion in profits. Earnings per share was 5.03.
| Revenue | 45.77B |
| Gross Profit | 37.31B |
| Operating Income | 11.33B |
| Pretax Income | 9.78B |
| Net Income | 7.87B |
| EBITDA | 15.17B |
| EBIT | 11.33B |
| Earnings Per Share (EPS) | 5.03 |
Balance Sheet
The company has 5.81 billion in cash and 25.77 billion in debt, with a net cash position of -19.96 billion or -12.87 per share.
| Cash & Cash Equivalents | 5.81B |
| Total Debt | 25.77B |
| Net Cash | -19.96B |
| Net Cash Per Share | -12.87 |
| Equity (Book Value) | 35.88B |
| Book Value Per Share | 23.14 |
| Working Capital | -2.24B |
Cash Flow
In the last 12 months, operating cash flow was 10.77 billion and capital expenditures -2.22 billion, giving a free cash flow of 8.55 billion.
| Operating Cash Flow | 10.77B |
| Capital Expenditures | -2.22B |
| Depreciation & Amortization | 3.80B |
| Net Borrowing | 893.76M |
| Free Cash Flow | 8.55B |
| FCF Per Share | 5.51 |
Margins
Gross margin is 81.51%, with operating and profit margins of 24.75% and 17.19%.
| Gross Margin | 81.51% |
| Operating Margin | 24.75% |
| Pretax Margin | 21.37% |
| Profit Margin | 17.19% |
| EBITDA Margin | 33.13% |
| EBIT Margin | 24.75% |
| FCF Margin | 18.68% |
Dividends & Yields
This stock pays an annual dividend of 2.36, which amounts to a dividend yield of 1.74%.
| Dividend Per Share | 2.36 |
| Dividend Yield | 1.74% |
| Dividend Growth (YoY) | -3.83% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 46.07% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.82% |
| Earnings Yield | 3.66% |
| FCF Yield | 3.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for AstraZeneca is 16,475.14, which is 18.89% higher than the current price. The consensus rating is "Buy".
| Price Target | 16,475.14 |
| Price Target Difference | 18.89% |
| Analyst Consensus | Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | 6.79% |
| EPS Growth Forecast (3Y) | 12.15% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.35 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 7 |